Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
Fourth-Quarter 2013 Non-GAAP EPS Increased by 6 Percent Over Prior Year to $0.88, Excluding Certain Items; GAAP EPS Decreased by 13 Percent to $0.26. Full-Year 2013 Non-GAAP EPS of $3.49, Excluding Certain Items; GAAP EPS of $1.47.
Fourth-Quarter 2013 Worldwide Sales Were $11.3 Billion, a Decrease of 4 Percent Reflecting Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange.
Full-Year 2013 Worldwide Sales Were $44.0 Billion, a Decrease of 7 Percent Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange.
Strong Full-Year Sales Growth for GARDASIL, REMICADE, SIMPONI, ISENTRESS, ZOSTAVAX and the Diabetes Franchise.
Returned $11 Billion to Shareholders in 2013 Through Dividends and Share Repurchases.
Accelerated Development Program for MK-3475, Including Announcement of Four Collaborations to Evaluate Novel Combination Regimens, Initiation of a Phase I Study in 20 New Cancer Types and Rolling Submission of a BLA to the FDA.
2014 Full-Year Non-GAAP EPS Target of $3.35 to $3.53, Excluding Certain Items; GAAP EPS Range of $2.15 to $2.47.
...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Cervical Cancer Vaccine | Diabetes | Endocrinology | Isentress | Merck | Pharmaceuticals | Remicade | Shingles (Herpes Zoster) Vaccine | Study | Varicella-Zoster Virus Vaccine